MingMed Biotechnology Co., Ltd. (hereinafter referred to as"MingMed") announced that its subsidiary, Zhuhai Yufan Biotechnology Co., Ltd. (hereinafter referred to as "Yufan Biotechnology"), will be in 2023Year11Month1Day toThe 3rd on the 5th in San Diego, USA8The Annual Meeting of the Society for Immunotherapy of Cancer (hereinafter referred to as“SITC 2023") presented in poster form its ongoing research on HPK1Small Molecule InhibitorPRJ1-3024Clinical data in the United States.
HPK1(Hematopoietic Progenitor Kinase1）Located inThe upstream pathway of PD-1 is a key kinase expressed in immune cells. It negatively regulates the functions of various immune cells in the anti-tumor immune cycle and can modulate the expression of PD-1 in T cells, making it a potential next-generation super target for immunotherapy. The development of small-molecule drugs targeting HPK1 has gained significant attention from pharmaceutical companies worldwide.PRJ1-3024Is the most advanced to enter the clinical stage globallyHPK1One of the inhibitors,InIn November 2021 and February 2022, PRJ1-3024 entered Phase I clinical trials in the United States and China, respectively, to evaluate its safety, tolerability, preliminary efficacy, and pharmacokinetic data for the treatment of advanced solid tumors.
ExceptPRJ1-3024In addition, Yufan Biotechnology will alsoSITC 2023Published its research inCBL-BSmall Molecule InhibitorYF550-C1Preclinical data.
About MingMed
MingMed is a Chinese enterprise that focuses on the independent research and development of innovative drugs and possesses global competitiveness. The company has a research and development team led by several globally renowned scientists and experts. With strong R&D capabilities and highly efficient operational abilities,ItsIndependently developed a series of diversified and synergistic product pipelines, including recombinant protein botulinum toxin, ophthalmic drugs, tumor immunotherapy drugs, and pet immunotherapy drugs, among which there are several potentialFirst-in-class innovative drugs, and all major products have entered the clinical stage.
